Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.
2.
3.

Chronic kidney disease and the skeleton.

Miller PD.

Bone Res. 2014 Dec 23;2:14044. doi: 10.1038/boneres.2014.44. eCollection 2014. Review.

4.

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

Moe SM, Chen NX, Newman CL, Organ JM, Kneissel M, Kramer I, Gattone VH 2nd, Allen MR.

J Bone Miner Res. 2015 Mar;30(3):499-509. doi: 10.1002/jbmr.2372.

5.

Safety of drugs used in the treatment of osteoporosis.

McGreevy C, Williams D.

Ther Adv Drug Saf. 2011 Aug;2(4):159-72. doi: 10.1177/2042098611411012. Review.

6.

Chronic kidney disease and osteoporosis: evaluation and management.

Miller PD.

Bonekey Rep. 2014 Jun 25;3:542. doi: 10.1038/bonekey.2014.37. eCollection 2014. Review.

7.

Bisphosphonate-induced Severe Hypocalcemia - A Case Report -.

Do WS, Park JK, Park MI, Kim HS, Kim SH, Lee DH.

J Bone Metab. 2012 Nov;19(2):139-45. doi: 10.11005/jbm.2012.19.2.139. Epub 2012 Nov 16.

8.

Bisphophonates in CKD patients with low bone mineral density.

Liu WC, Yen JF, Lang CL, Yan MT, Lu KC.

ScientificWorldJournal. 2013 Dec 31;2013:837573. doi: 10.1155/2013/837573. eCollection 2013. Review.

9.

Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Warriner AH, Saag KG.

Curr Osteoporos Rep. 2013 Dec;11(4):341-7. doi: 10.1007/s11914-013-0173-0. Review.

10.

A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.

Moe SM, Chen NX, Newman CL, Gattone VH 2nd, Organ JM, Chen X, Allen MR.

J Bone Miner Res. 2014 Apr;29(4):902-10. doi: 10.1002/jbmr.2089.

11.

Recent advances in the noninvasive diagnosis of renal osteodystrophy.

Moorthi RN, Moe SM.

Kidney Int. 2013 Nov;84(5):886-94. doi: 10.1038/ki.2013.254. Epub 2013 Jun 26. Review.

12.

Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Lewiecki EM.

Ther Adv Chronic Dis. 2010 May;1(3):115-28. doi: 10.1177/2040622310374783.

13.

A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Benhamou CL, Man Z, Tlustochowicz W, Zanchetta JR, Eusebio R, Balske AM, Matzkin E, Olszynski WP, Recker R, Delmas PD.

Calcif Tissue Int. 2013 Jan;92(1):59-67. doi: 10.1007/s00223-012-9668-4. Epub 2012 Nov 13.

14.

Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.

Allen MR, Chen NX, Gattone VH 2nd, Chen X, Carr AJ, LeBlanc P, Brown D, Moe SM.

Osteoporos Int. 2013 Apr;24(4):1471-81. doi: 10.1007/s00198-012-2103-x. Epub 2012 Aug 21.

15.

Osteoporosis in men: insights for the clinician.

Adler RA.

Ther Adv Musculoskelet Dis. 2011 Aug;3(4):191-200. doi: 10.1177/1759720X11411600.

16.

Use of oral bisphosphonates by older adults with fractures and impaired renal function.

Sadowski CA, Spencer T, Yuksel N.

Can J Hosp Pharm. 2011 Jan;64(1):36-41.

17.

Risedronate's efficacy: from randomized clinical trials to real clinical practice.

Iolascon G, Sirico F, Ferrante A, Gimigliano R, Gimigliano F.

Clin Cases Miner Bone Metab. 2010 Jan;7(1):19-22.

18.

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY.

Osteoporos Int. 2012 Feb;23 Suppl 1:S1-23. doi: 10.1007/s00198-011-1891-8. Epub 2012 Feb 4.

19.

Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.

Gates BJ, Das S.

Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:1-14. doi: 10.4137/CMAMD.S4092. Epub 2012 Jan 5.

20.

Updated recommendations for the diagnosis and management of osteoporosis: a local perspective.

Raef H, Al-Bugami M, Balharith S, Moawad M, El-Shaker M, Hassan A, Al-Shaikh A, Al-Badawi I; King Faisal Specialist Hospital Osteoporosis Working Group..

Ann Saudi Med. 2011 Mar-Apr;31(2):111-28. doi: 10.4103/0256-4947.77502.

Supplemental Content

Support Center